Albert M. Kim, MD, PhD

Adjunct Instructor, Medicine

Albert Kim
72 E. Concord St Building A

Biography

Dr. Kim is an accomplished physician-scientist with expertise in cardiovascular disease, translational medicine, and drug development. He earned his undergraduate degree in biomedical engineering from Harvard, MD and PhD degrees from UCLA, completed internal medicine residency at Brigham and Women’s Hospital, cardiology fellowship training at MGH, and clinical cardiac electrophysiology training at UCSF. He joined the UCSF faculty and subsequently transitioned to the pharmaceutical industry as a Senior Translational Medicine Expert at Novartis, where he led small molecule and biologic asset programs for hyperlipidemia, inflammation, atherosclerosis, and arrhythmia indications. In 2013 he joined the Pfizer Cardiovascular and Metabolic (CVMET) Research Unit in Cambridge, MA and has served in multiple leadership roles over the past 4 years. He currently serves as VP, Clinical Research Head for CVMET, and oversees clinical research efforts for cardiometabolic diseases such as NASH, diabetes, obesity and heart failure. He has served in advisory and supervisory roles for cardiovascular safety and pharmacovigilance activities, and worked at the FDA in the Division of Cardiac Devices as a medical reviewer and project lead for the industry guidance document on catheter ablation for atrial fibrillation. Beyond his roles at Pfizer, he also holds academic appointments in the VA Boston Cardiac Electrophysiology Section, at Boston University, and at Harvard Medical School.

Other Positions

  • VA Boston Healthcare System

Education

  • University of California, Los Angeles, MD
  • University of California, Los Angeles, PhD
  • Harvard College, AB

Publications

  • Published on 10/11/2021

    Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, Aggarwal S, Crowley C, Rinaldi A, Mancuso J, Aggarwal N, Somayaji V, Inglot M, Tuthill TA, Kou K, Boucher M, Tesz G, Dullea R, Bence KK, Kim AM, Pfefferkorn JA, Esler WP. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med. 2021 10; 27(10):1836-1848. PMID: 34635855.

    Read at: PubMed
  • Published on 6/14/2021

    Saxena AR, Gorman DN, Esquejo RM, Bergman A, Chidsey K, Buckeridge C, Griffith DA, Kim AM. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med. 2021 06; 27(6):1079-1087. PMID: 34127852.

    Read at: PubMed
  • Published on 11/27/2019

    Amin NB, Carvajal-Gonzalez S, Purkal J, Zhu T, Crowley C, Perez S, Chidsey K, Kim AM, Goodwin B. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci Transl Med. 2019 11 27; 11(520). PMID: 31776293.

    Read at: PubMed
  • Published on 3/19/2019

    Roth Flach RJ, Su C, Bollinger E, Cortes C, Robertson AW, Opsahl AC, Coskran TM, Maresca KP, Keliher EJ, Yates PD, Kim AM, Kalgutkar AS, Buckbinder L. Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition. PLoS One. 2019; 14(3):e0214150. PMID: 30889221.

    Read at: PubMed
  • Published on 7/18/2018

    Bass A, Plotka A, Mridha K, Sattler C, Kim AM, Plowchalk DR. Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trial. Health Sci Rep. 2018 Sep; 1(9):e61. PMID: 30623096.

    Read at: PubMed
  • Published on 4/1/2018

    Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, Wasserman SM, Wiklund O, Zouridakis E. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother. 2018 04 01; 4(2):119-127. PMID: 29194462.

    Read at: PubMed
  • Published on 7/21/2017

    Kim AM, Somayaji VR, Dong JQ, Rolph TP, Weng Y, Chabot JR, Gropp KE, Talukdar S, Calle RA. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. Diabetes Obes Metab. 2017 Dec; 19(12):1762-1772. PMID: 28573777.

    Read at: PubMed
  • Published on 3/27/2017

    Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail. 2017 Jun; 19(6):718-727. PMID: 28345190.

    Read at: PubMed
  • Published on 3/17/2017

    Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017 04 20; 376(16):1517-1526. PMID: 28304227.

    Read at: PubMed
  • Published on 6/1/2016

    Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Floch CL, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489]. Eur J Heart Fail. 2016 06; 18(6):727. PMID: 27324688.

    Read at: PubMed

View 18 more publications: View full profile at BUMC

View all profiles